Alzheimer’s disease is an age-related, neurodegenerative disorder, characterized by cognitive impairment and restrictions in activities of daily living. This disease is the most common form of dementia with complex multifactorial pathological mechanisms. Many therapeutic approaches have been proposed. Among them, inhibition of acetylcholinesterase, butyrylcholinesterase, and prolyl oligopeptidase can be beneficial targets in the treatment of Alzheimer’s disease. Roots, along with aerial parts of *Argemone platyceras*, were extracted with ethanol and fractionated on an alumina column using light petrol, chloroform and ethanol. Subsequently, repeated preparative thin-layer chromatography led to the isolation of (+)-laudanosine, protopine, (–)-argemonine, allocryptopine, (–)-platycerine, (–)-munitagine, and (–)-norargemonine belonging to pavine, protopine and benzyltetrahydroisoquinoline structural types. Chemical structures of the isolated alkaloids were elucidated by optical rotation, spectroscopic and spectrometric analysis (NMR, MS), and comparison with literature data. (+)-Laudanosine was isolated from *A. platyceras* for the first time. Isolated compounds were tested for human blood acetylcholinesterase, human plasma butyrylcholinesterase and recombinant prolyl oligopeptidase inhibitory activity. The alkaloids inhibited the enzymes in a dose-dependent manner. The most active compound (–)-munitagine, a pavine alkaloid, inhibited both acetylcholinesterase and prolyl oligopeptidase with IC$_{50}$ values of $62.3 \pm 5.8 \, \mu M$ and $277.0 \pm 31.3 \, \mu M$, respectively.

Keywords: *Argemone platyceras*; alkaloids; acetylcholinesterase; butyrylcholinesterase; prolyl oligopeptidase; Alzheimer’s disease

1. Introduction

Alzheimer’s disease (AD) is an age-related, progressive, neurodegenerative disorder, with onset usually in later life. The disease is characterized by cognitive impairment, a variety of behavioral symptoms and restrictions in activities of daily living. AD is the most common form of dementia and the prevalence increases exponentially between the ages 65 to 85, doubling with every 5-year age group [1]. AD has two characteristic pathological hallmarks: extracellular accumulation of $\beta$-amyloid...
peptide (amyloid plaques), and intraneuronal formation of hyperphosphorylated τ-protein filaments (neurofibrillary tangles) leading to progressive loss of neurons and disintegration of the neural circuits, particularly in the cerebral cortex [2,3]. Use of the current available drugs in AD mostly relies on the cholinergic hypothesis supported by several observations that decreases in cholinergic transmission in the neocortex and hippocampus correlate with dementia severity [1]. Both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are responsible for the breakdown of acetylcholine (ACh) in the synapses [4]. As AD progresses in severity, AChE concentrations and activity decrease and those of BChE increase [4–6]. In the normal brain, the relative proportions of cholinesterase activity are 99% for AChE and 1% for BChE; in advanced AD, the corresponding proportions are 65% and 35% (a change in ratio from 99:1 to 2:1) for AChE and BChE, respectively [5,7,8]. At advanced stages of this disorder, BChE may replace AChE in hydrolyzing brain ACh [5]. Therefore, inhibition of both enzymes can be beneficial to treat symptoms in AD [1]. Research focused on cholinesterase inhibitors of plant origin discovered that alkaloid extracts of some Papaveraceae species demonstrated interesting cholinesterase inhibitory activity [9–12].

Prolyl oligopeptidase (POP), also known as prolyl endopeptidase, represents another potential therapeutic hit in the treatment of AD. POP is an enzyme that cleaves peptides with a relatively small molecular weight at the carboxyl side of a proline residue, such as vasopressin, thyrotropin-releasing hormone, and substance P. POP is distributed in over 20 human tissue types with the highest activity found in skeletal muscles and the human brain, especially in the cortex. Previous studies suggested that POP could be related to neurodegeneration and disturbances in memory and cognition. Abnormal levels of POP activity have been found to be significantly higher in Alzheimer patients’ brains than in control patients [13]. The exact mechanism of memory and learning improving action of POP inhibitors is not yet fully explained and is still under study [14–16]. Inhibitors of POP may improve memory by blocking the metabolism of endogenous neuropeptides [13]. Neuropeptides such as vasopressin or thyrotropin-releasing hormone as well as substance P were described as cognition enhancers with positive modulatory effects on cerebral cholinergic activity. It has also been demonstrated that several neuropeptides can promote processes related to functional recovery following central nervous system damage. Deficiencies in substance P and vasopressin have been reported in postmortem studies of cerebral tissue derived from patients with neurodegenerative diseases [17]. A beneficial effect on mnemonic-cognitive performance has been seen in patients with AD following thyrotropin-releasing hormone treatment [18,19]. Furthermore, POP might be involved in the processing of the C-terminal portion of the amyloid precursor protein, which has been revealed to injure neurons [20,21], suggesting that POP inhibitors may decrease the amyloid deposition [22]. However, a role of POP in the processing or degradation of β-amylloid appears to be unclear; POP could be associated with neuronal damage rather than β-amylloid accumulation [23]. Several in vivo experiments in animal models showed that POP inhibition led to neuroprotective, cognition-enhancing, and memory-enhancing effects; short-term, long-term, reference and working memory were positively influenced [14]. Some clinical trials with POP inhibitors in the treatment of cognitive deficits have been performed. The most reported compound was S-17092. It showed cognition-enhancing properties in healthy elderly subjects and could improve a delayed verbal memory task [24]. In addition, some mood-stabilizing potential in healthy young volunteers has been observed [25]. Thus, POP-inhibiting compounds appear as a promising therapeutic approach to the treatment of AD. POP inhibitors were also found among natural products of different structural types (e.g., phenolics, benzofurans, terpenes, peptides, and alkaloids) [13,26–29].

Argemone platyceras Link et Otto, a species of prickly poppy, belonging to the family Papaveraceae, is a spiny annual herb with incised leaves and white flowers [30]. The plant is widely distributed throughout Mexico and is commonly known as “chicalota”, which is used in the form of flower infusion for cough, bronchitis and pneumonia [31]. Two groups of secondary metabolites are documented for A. platyceras: isoquinoline alkaloids and flavonoids (isoquercitrin and rutin) [31]. Many tertiary and quaternary isoquinoline alkaloids have been found
in *A. platyceras* (Table 1), the major ones being (−)-platycerine, (−)-munitagine, (−)-argemonine and protopine in the overground parts [32–35], and protopine in the roots [33].

| Alkaloid                        | Plant Part [Literature]                  |
|---------------------------------|-----------------------------------------|
| (−)-platycerine                 | aerial parts [33–35], roots [33]        |
| (−)-munitagine                   | aerial parts [35], aerial parts + roots [36] * |
| (−)-argemonine                   | aerial parts [33–35], aerial parts + roots [36] * |
| protopine                        | aerial parts [32–35], roots [33]        |
| (+)-reticuline                   | aerial parts [35], aerial parts + roots [36] * |
| (−)-norargemonine                | aerial parts [32–34], roots [33]        |
| allocryptopine                   | aerial parts [32,34,35], roots [33]     |
| chelerythrine                    | aerial parts [34]                       |
| coptisine                        | aerial parts [33,34], roots [33,37]     |
| berberine                        | aerial parts [33–35], roots [33,37]     |
| (−)-O-methylplatycerine          | aerial parts [35]                       |
| enyssamine                       | aerial parts [34], roots [37]           |
| sanguinarine                     | aerial parts [33–35], roots [33]        |
| (−)-scoulerine                   | aerial parts + roots [36] *             |
| (−)-platycerine methohydroxide   | aerial parts [34], roots [37]           |
| (−)-argemonine methohydroxide    | aerial parts [34]                       |
| (−)-α-stylopine methohydroxide   | aerial parts [34,35], roots [37]        |
| (−)-α-magnoflorine               | aerial parts [35], roots [37]           |
| (−)-α-canadine methohydroxide    | roots [37]                              |
| (−)-cyclanoline                  | roots [37]                              |
| armepavine                       | aerial parts [38] **                    |
| escholtzine                      | aerial parts [38] **                    |
| isonorargemonine                 | aerial parts [38] **                    |
| bisnorargemonine                 | aerial parts [38] **                    |
| cryptocavine                     | aerial parts [38] **                    |
| cryptopalmatine                  | aerial parts [38] **                    |

* Alkaloids isolated from 90% aerial parts + 10% roots; ** alkaloids identified by means of GC-MS in a plant extract, but not isolated.

No systematic studies have been reported regarding the pharmacological properties of *A. platyceras*. Methanol extracts of the leaves and flowers showed anti-asthmatic activity in an allergic asthma model (isolated guinea pig trachea), and bioassay-guided fractionation led to isoquercitrin being found as the active principle responsible for it [31].

This study deals with the isolation of tertiary alkaloids from the aerial parts and roots of *A. platyceras* (quaternary alkaloids might have problems to cross the blood-brain barrier [39]), and their ability to inhibit erythrocyte AChE and plasma BChE from human blood. Additionally, these compounds were also tested for their inhibitory activity on recombinant POP, since it has been found that some isoquinoline alkaloids possess a POP inhibitory effect [27].

2. Results and Discussion

2.1. Choice of Plant Material

During a screening focused on cholinesterase inhibitors of plant origins, we found a promising cholinesterase inhibitory activity of an ethyl-acetate alkaloid extract of *A. platyceras* aerial parts and roots with IC$_{50}$ values for AChE of 15.7 ± 2.9 µg/mL and IC$_{50}$ BChE of 25.5 ± 1.8 µg/mL. Galanthamine, huperzine A and eserine were used as positive controls.
2.2. Isolated Alkaloids

Column chromatography (CC) and subsequent preparative thin-layer chromatography (TLC) led to the isolation of seven compounds (1–7) belonging to pavine, protopine and benzylisoquinoline structural types. The chemical structures of the isolated alkaloids were elucidated by means of optical rotation, spectroscopic (1H- and 13C-NMR) and spectrometric (GC-MS, ESI) analyses and by comparison of the obtained data with those in the literature [17–36,38,40–47]. The compounds were determined as (+)-laudanosine (1), protopine (2), (–)-argemonine (3), allocryptopine (4), (–)-platycerine (5), (–)-munitagine (6) and (–)-norargemonine (7) (Figure 1).

This study is the first report about the isolation of (+)-laudanosine (1), an opium alkaloid, from A. platyceras. In the genus Argemone compound 1 has been identified as a minor alkaloid in A. grandiflora only [48]. Laudanosine, arising from the key branch point intermediate (+)-reticuline, as other benzylisoquinoline alkaloids, belongs to the benzyltetrahydroisoquinolines [49]. The remaining alkaloids (2–7) have been previously isolated from A. platyceras (Table 1). The protopine alkaloids protopine (2) and allocryptopine (4) are very common in species of Papaveraceae, Fumariaceae, Berberidaceae, Rutaceae, Ranunculaceae, and Sapindaceae. Protopines possess, as free tricyclic bases, a ten-membered heterocyclic ring containing one tertiary nitrogen and carbonyl group, and, under acidic conditions, they form tetracyclic salts [50]. (–)-Argemonine (3), (–)-platycerine (5), (–)-munitagine (6) and (–)-norargemonine (7) belong to a small group of alkaloids called pavines, which are all derived from benzylisoquinolines functionalized in the ring B. Pavines are found in four plant families, namely Papaveraceae, Berberidaceae, Lauraceae, and Ranunculaceae. Within the Papaveraceae, pavines are known to occur in the genera Argemone and Eschscholtzia [51].
2.3. Cholinesterase Inhibitory Activity of Isolated Alkaloids

NMNDA blockers and cholinesterase inhibitors (ChEIs) are used in AD therapy [52-54] and are being tested in clinical trials [53,54]. The spectrum of therapeutically used drugs is limited; the U.S. Food and Drug Administration (FDA) has approved donepezil, galanthamine and rivastigmine as ChEIs to treat the symptoms of mild to moderate AD. All these drugs inhibit both enzymes, but with different potency. From the pharmacological point of view, galanthamine and donepezil are positive controls (Table 2). The isolated tertiary isoquinoline alkaloids showed weaker cholinesterase inhibition than the standards. (–)-Munitagine (6) was the most potent compound inhibiting AChE in a dose-dependent manner with an IC_{50} = 62.3 ± 5.8 µM (Figure 2). Moreover, 6 was found to be a selective inhibitor of AChE: towards BChE it was considered almost inactive (IC_{50} = 837.4 ± 23.0 µM). Pavines, according to our obtained results (3, 5–7) and those reported in the literature [58], possess either weak or no activity on BChE (IC_{50} > 837.4 µM), but generally show mild AChE inhibitory activity, excluding the moderate AChE inhibitors (–)-munitagine, (–)-caryachine and (–)-californidine with IC_{50} values of 62.3 ± 5.8 µM, 19.6 ± 0.4 µM [58] and 36.7 ± 0.9 µM [58], respectively.

Table 2. A. platyceras alkaloids and their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and prolyl oligopeptidase (POP) inhibitory activity.

| Compounds         | AChE (IC_{50}, µM) | BChE (IC_{50}, µM) | POP (IC_{50}, µM) |
|-------------------|--------------------|--------------------|-------------------|
| 1                 | >1000              | >1000              | 341.0 ± 37.5      |
| 2                 | 230.0 ± 21.0       | 208.9 ± 17.7       | >1000             |
| 3                 | >1000              | 885.5 ± 119.5      | 337.0 ± 83.1      |
| 4                 | 250.0 ± 25.0       | 530.0 ± 28.2       | >1000             |
| 5                 | 223.7 ± 19.6       | >1000              | 687.0 ± 74.0      |
| 6                 | 62.3 ± 5.8         | 837.4 ± 23.0       | 277.0 ± 31.3      |
| 7                 | 205.2 ± 11.7       | >1000              | n.d.              |
| Galanthamine *    | 1.71 ± 0.07        | 42.30 ± 1.3        | n.d.              |
| Huperzine A       | 0.033 ± 0.001      | >1000              | n.d.              |
| Serine *          | 0.063 ± 0.001      | 0.13 ± 0.004       | n.d.              |
| Berberine *       | n.d.               | n.d.               | 142.0 ± 21.5      |
| Z-Pro-prolinal *  | n.d.               | n.d.               | 3.27 ± 0.02 × 10^{-3} |

* Results are the means ± S.E.M. of three independent replications; b reference [27]; c insufficient amounts for assay measurement; standard; n.d. not determined.

Figure 2. The dose-response curve of (–)-munitagine (IC_{50} calculation of its AChE inhibitory activity).
Furthermore, in our work, the protopine alkaloids, protopine (2) and allocryptopine (4), demonstrated mild cholinesterase inhibition (protopine: IC₅₀ AChE = 230.0 ± 21.0 µM; IC₅₀ BChE = 208.9 ± 17.7 µM), and allocryptopine IC₅₀ AChE = 250.0 ± 25.0 µM; IC₅₀ BChE = 530.0 ± 28.2 µM. Contrary to our results, in the review of Sener and Orhan, it is mentioned that protopine and allocryptopine, isolated as active substances from *Fumaria vaillantii*, were identified as potent AChE inhibitors with IC₅₀ values of 1.8 and 1.3 µM, respectively [59]. The contrasting results for AChE inhibitory activity of protopine and allocryptopine could be explained by the use of different conditions in the assays e.g., the source of enzyme (AChE from electric eel or human AChE), concentration of substrate (acetylthiocholine)–protopine was found to be a dose-dependent, specific, reversible and competitive AChE inhibitor [50]. Thus, it is very difficult to compare the obtained data with those in the literature, and for the explanation of the cholinesterase activity of these compounds, further biological studies are needed.

Finally, (+)-laudanosine (1), a benzyltetrahydroisoquinoline with four methoxy substituents on the skeleton, was considered inactive on cholinesterases, with IC₅₀ values for AChE and BChE > 1000 µM. This compound has not been tested for its ability to inhibit cholinesterase so far. In comparison to the cholinesterase inhibitory activity of benzylisoquinolines in the literature to our found results of 1, it seems that cholinesterase inhibitory activity of this structural type is connected to the presence of one hydroxyl (OH) group on the benzene ring at positions 3' or 4' in the case of the 6-hydroxy-7-methoxybenzylisoquinolines. For instance, (+)-reticuline and (+)-N-methylcoclaurine, which are selective BChE inhibitors with IC₅₀ values of 33.6 ± 3.0 and 15.0 ± 1.4 µM (IC₅₀ values for AChE inhibition were >220 µM) [60]. 6,7-Methyldioxybenzylisoquinoline with OH and methoxy groups at the 3' and 4' positions on the benzene ring, respectively, showed similar anti-BChE activity to reticuline (IC₅₀ BChE = 28 µM; IC₅₀ AChE = 102 µM) [58]. Furthermore, the 6,7-methyldioxy substituent on the benzylisoquinoline skeleton seems to be responsible for better AChE inhibition. The above mentioned compound and (+)-canadaline inhibited AChE, with canadaline giving an IC₅₀ value of 20.1 µM [61]. The study of Markmee et al. has provided more insights into the SAR of 1-benzylisoquinoline derivatives on AChE inhibition [62]. Additional studies are underway to determine structural requirements of this class of benzylisoquinolines. Considering that the EtOAc alkaloid extract of *A. platyceras* demonstrated promising cholinesterase inhibitory activity with values for IC₅₀ AChE of 15.7 ± 2.9 µg/mL and IC₅₀ BChE of 25.5 ± 1.8 µg/mL. It seems that the resultant activity was not caused by a synergistic effect of the isolated compounds [63], but probably due to the presence of quaternary alkaloids in the extract (chelerythrine, berberine, coptisine, and sanguinarine are very potent inhibitors of cholinesterases) [64–67], and they were found in this plant (Table 1). Additionally, most of these quaternary alkaloids are soluble in some lipophilic solvents [68,69].

### 2.4. Prolyl Oligopeptidase Inhibitory Activity of Isolated Alkaloids

Similarly, POP has been suggested to participate in the pathogenesis of AD, and, therefore, POP inhibition can become another supporting therapeutic approach in AD treatment. Consequently, given the complexity and interconnected pathological pathways of the disease, the research focused on compounds influencing more therapeutic targets (a multi-target drug approach) involved in AD is needed. Thus, finding of inhibitors with anti-cholinesterase and POP inhibitory activity maybe provide a more effective treatment of AD.

Compounds isolated in sufficient amounts (1–6) were tested for their ability to inhibit POP and our data correspond with those in the literature [27]. Z-Pro-prolinal (a synthetic compound) and berberine were used as positive standards with IC₅₀ values of 3.27 ± 0.02 nM and 142.0 ± 21.5 µM, respectively. None of the isolated alkaloids demonstrated a similar potent inhibition as the reference compounds. The most active of the isolated compounds were (−)-munitagine (6), (−)-argemonine (3) and (+)-laudanosine (1), with IC₅₀ values of 277.0 ± 31.3 µM, 337.0 ± 83.1 µM and 341.0 ± 37.5 µM, respectively (Figure 3). (−)-Platycerine (3), isolated and tested for POP inhibition previously [27], was a twofold weaker POP inhibitor than (−)-argemonine; its IC₅₀ was 687.0 µM. Protopine (2) and
allocryptopine (4) were considered inactive (IC\textsubscript{50} > 1000 \(\mu\text{M}\)). It seems that benzylisoquinoline and pavine types possess anti-POP activity, reversely; protopines lack POP activity.

![Figure 3](image-url)

**Figure 3.** The dose-response curves of the most potent POP inhibitors (–)-munitagine, (+)-laudanosine and (–)-argemonine (calculation of their IC\textsubscript{50} values).

3. Experimental

3.1. Plant Material

Seeds of *A. platyceras* for the plant cultivation were obtained from the Centre of Medicinal Plants of Faculty of Medicine, Masaryk University in Brno, the Czech Republic, in 2012. Plants were cultivated in the Botanical Garden of Medicinal Plants of the Faculty of Pharmacy in Hradec Králové, Charles University, the Czech Republic in 2013; the collection of the plants was in the same year. Prof. Dr. L. Opletal performed botanical identification and verification. A voucher specimen has been deposited in the herbarium of the Faculty of Pharmacy in Hradec Králové.

3.2. General Experimental Procedures

\(^1\)H-NMR (500 MHz) and \(^13\)C-NMR (125.7 MHz) spectra were recorded on a VNMR S500 NMR spectrometer (Varian, Palo Alto, CA, USA). The ESI-MS (electrospray ionization mass spectrometry) analysis was performed on a Thermo Finnigan LCQDuo spectrometer and EI-MS on an Agilent 7890A GC 5975 inert MSD operating in EI mode at 70 eV (Agilent Technologies, Santa Clara, CA, USA). A DB-5 column (30 m × 0.25 mm × 0.25 \(\mu\text{m}\), Agilent Technologies, USA) was used. The temperature program was set at 100–180 °C at 15 °C/min, 1 min hold at 180 °C and 180–300 °C at 5 °C/min and 5 min hold at 300 °C, detection range \(m/z\) 40–600. The injector temperature was 280 °C. The flow-rate of carrier gas (helium) was 0.8 mL/min. A split ratio of 1:10 was used. Optical rotation was measured on an P3000 polarimeter (A. Krüss Optronic, Germany) in chloroform (CHCl\textsubscript{3}). TLC was carried out on Merck pre-coated silica gel 60 F254 plates and for visualization of alkaloids on the TLC plates UV detection (254 and 366 nm) and spraying with Dragendorff’s reagent were performed. As solvents for mobile phases of TLC were used diethylamine (Et\textsubscript{2}NH), cyclohexane (C\textsubscript{6}H\textsubscript{12}), toluene (C\textsubscript{6}H\textsubscript{5}CH\textsubscript{3}), ethyl-acetate (EtOAc), acetone (DMK) and aqueous ammonia solution (NH\textsubscript{4}OH) (Penta, Ing. Švec, Praha, Czech Republic), and trifluoroacetic acid (TFAA, Sigma Aldrich). Neutral aluminum oxide (Al\textsubscript{2}O\textsubscript{3}; 50–200 \(\mu\text{m}\); Lach-Ner, Neratovice, Czech Republic) was used for CC.

3.3. Extraction and Isolation of Alkaloids

Dried and powdered aerial parts, along with roots, of *A. platyceras* (7.95 kg; 7.52 kg and 0.43 kg, respectively) were extracted with EtOH (96\%, 2×) at room temperature for 48 h. The combined macerate was filtered and evaporated to dryness and a dark-greenish viscous crude extract (190 g) was obtained. To the extract, 2 L H\textsubscript{2}O was added, the suspension was heated to 70 °C and acidified with 2\% HCl to pH~1, filtered, and the filtrate was alkaliized with 10\% Na\textsubscript{2}CO\textsubscript{3} to pH 9–10 and
tertiary alkaloids were exhaustively extracted with CHCl₃ (3 × 700 mL). The remaining quaternary alkaloids in the water phase were not further processed. The organic layer was evaporated to give 19 g of a dark-brown viscous alkaloid concentrate, which was subsequently purified by dissolving in 2% HCl, filtered, extracted with diethyl ether (Et₂O; 2 × 200 mL) to remove non-alkaloid compounds, and finally extracted with 10% Na₂CO₃ and with Et₂O (4 × 300 mL). The Et₂O layer was treated with 2% HCl (4 × 150 mL), subsequently alkalized with Na₂CO₃, and the water layer extracted with Et₂O (3 × 300 mL). The combined Et₂O extract was evaporated to give 10.35 g of the brownish viscous extract. This was further fractionated by CC on neutral Al₂O₃ eluting with light petrol + CHCl₃ (4:1, 3:1, 1:3, 1:1, 1:3), CHCl₃ and CHCl₃ + EtOH (1:1). Fractions (250 mL) were collected and monitored by TLC leading to 144 fractions that were combined into 8 (A–H) fractions. Preparative TLC (C₆H₁₂ + Et₂NH, 9:1, 2 ×) of fraction A (220 mg) led to the isolation of amorphous white compound 1 (18 mg). Crystallization of fraction C (1.68 g) from CHCl₃ + EtOH (1:1) led to compound 2 (900 mg). The parent residue (720 mg) was subjected to preparative TLC (C₆H₁₂ + C₆H₅CH₃ + Et₂NH, 45:45:10, 2 ×) to give 2 sub-fractions C1 (20 mg), and C2 (90 mg) from which white crystalline compound 3 (27.6 mg) was obtained by crystallization from 25% aqueous EtOH. Crystallization of fraction E (white powder, 66 mg) from CHCl₃ + EtOH (1:1) led to compound 4 (52 mg). Fraction F (3.24 g) was treated with 2% HCl, then alkalized and extracted with Et₂O. Subsequent repeated crystallization from Et₂O led to the isolation of compound 5 (white powder, 500 mg; [11]). Fraction G (762 mg) was treated by preparative TLC (EtOAC + ACN + TFAA, 40:5:0.1, Et₂O) resulting in 2 sub-fractions G1-2. Repeated crystallization of G1 (200 mg) gave compound 6 as a white crystalline powder (31.5 mg). Sub-fraction G2 (159 mg) was further chromatographed by preparative TLC (C₆H₁₂ + DMK + NH₃, 45:45:10, 2 ×) to give compound 7 (7.1 mg). Based on GC-MS and TLC analysis, fractions B (650 mg), D (230 mg) and H (353 mg) were not further separated to give pure compounds (presence of compounds previously found in the above-mentioned fractions C and E; fraction H due to trace amount of detected alkaloids).

3.4. Characterization Data

(+)-Laudanosine (1): amorphous white solid; [α]²⁵_D = +34° (c 1.96; CHCl₃); EI-MS (m/z) 357 (1); 206 (100), 190 (12); ESI-MS m/z [M + H]^+ 358 (100), 218 (10), 206 (6); ¹H-NMR (500 MHz, CDCl₃) δ 6.78 (1H, d, J = 8.1 Hz, H5'), 6.65 (1H, dd, J = 8.1 Hz, J = 2.1 Hz, H6'), 6.62 (1H, d, J = 2.1 Hz, H2'), 6.57 (1H, s, H5), 6.07 (1H, s, H8), 3.86 (3H, s, OCH₃), 3.85 (3H, s, OCH₃), 3.80 (3H, s, OCH₃), 3.74–3.69 (1H, m, H1), 3.59 (3H, s, OCH₃), 3.23–3.13 (2H, m, H3, H1'), 2.89–2.75 (3H, m, H3, H4', H1'), 2.65–2.57 (1H, m, H4), 2.56 (3H, s, NCH3); ¹³C-NMR (125 MHz, CDCl₃) δ 148.6, 147.4, 147.3, 146.3, 132.4, 129.7, 125.9, 121.9, 113.0, 111.2, 111.1, 111.0, 64.9, 55.9, 55.8, 55.6, 55.2, 54.6, 42.6, 40.9, 25.4.

Protopine (2): white crystals; m.p. 206–207 °C; EI-MS m/z 353 (5), 190 (10), 163 (25), 148 (100); ¹H-NMR (500 MHz, CDCl₃) δ 6.90 (1H, s, H1), 6.68 (1H, d, J = 8.0 Hz, H11), 6.65 (1H, d, J = 8.0 Hz, H12), 6.63 (1H, s, H4), 5.94 (2H, s, H15), 5.91 (2H, s, H16), 3.96–3.69 (2H, m, H13), 3.69–3.45 (2H, m, H8), 3.23–2.84 (1H, m, H5), 2.76–2.40 (3H, m, H3, H6, H6'), 1.95 (3H, s, NCH₃); ¹³C-NMR (125 MHz, CDCl₃) δ 192.4 (C14), 148.0 (C3), 146.2 (C9), 146.0 (C10), 145.9 (C2), 135.8 (C14a), 132.5 (C4a), 128.8 (C12a), 124.9 (C12), 117.6 (C8a), 110.4 (C4), 108.0 (C1), 106.7 (C11), 101.2 (C15), 100.8 (C16), 57.7 (C6), 50.9 (C8), 46.2 (C13), 41.5 (NCH₃), 31.5 (C5).

(-)-Argemonine (3): white crystals; m.p. 152–153 °C; [α]²⁵_D = -202° (c 0.51; CHCl₃); EI-MS (m/z) 355 (30), 354 (20), 204 (100); ¹H-NMR (500 MHz, CDCl₃) δ 6.62 (2H, s, H4, H10), 6.46 (2H, s, H1, H7), 4.01 (2H, d, J = 5.9 Hz, H5, H11), 3.86 (6H, s, OCH₃), 3.79 (6H, s, OCH₃), 3.41 (2H, dd, J = 16.1 Hz, J = 5.9 Hz, H6, H12), 2.60 (2H, d, J = 16.1 Hz, H6, H12), 2.54 (3H, s, NCH₃); ¹³C-NMR (125 MHz, CDCl₃) δ 147.8, 147.5, 130.0, 123.9, 113.5, 110.0, 56.4, 55.9, 55.7, 40.9, 33.6.

Allocryptopine (4): white crystals; m.p. 159–161 °C; EI-MS (m/z) 369 (5), 354 (5), 283 (15),206 (20), 164 (100), 162 (25), 149 (30), 134 (25); ¹H-NMR (500 MHz, CDCl₃) δ 6.95 (1H, s); 6.91 (1H, d); 6.80 (1H, d,
J = 8.24 Hz); 6.63 (1H, s); 3.86 (3H, s); 3.78 (3H, s); 3.72 (2H, bs); 2.2–3.5 (3H, m); 1.86 (3H, s); 13C-NMR (125 MHz, CDCl₃) δ 193.6, 151.8, 148.3, 147.9, 146.6, 136.3, 133.1, 129.8, 128.8, 128.0, 110.8, 110.7, 109.5, 101.4, 61.0, 57.8, 55.9, 50.4, 46.5, 41.4, 32.6.

(–)-Platycerine (5): white crystals; m.p. 130–131 °C; [α]D25 = −264° (c 0.43; CHCl₃); EI-MS (m/z) 341(42), 340 (25), 204 (100), 190 (28); 1H-NMR (500 MHz, CDCl₃) δ 6.67 (1H, d, J = 8.3 Hz, H2), 6.60 (1H, s, H10), 6.52 (1H, d, J = 8.3 Hz, H1), 6.46 (1H, s, H7), 5.97 (1H, bs, OH), 4.46 (1H, d, J = 5.7 Hz, H5), 4.09 (1H, d, J = 5.7 Hz, H11), 3.85 (3H, s, OCH₃), 3.82 (3H, s, OCH₃), 3.77 (3H, s, OCH₃), 3.48 (1H, d, J = 5.7 Hz, H12), 3.40 (1H, d, J = 5.7 Hz, H6), 2.80 (1H, d, J = 16.5 Hz, H5), 2.69 (1H, d, J = 16.5 Hz, H6), 2.62 (1H, d, J = 16.1 Hz, H6), 2.55 (3H, s, NCH₃); 13C-NMR (125 MHz, CDCl₃) δ 147.9, 147.5, 144.3, 141.9, 128.6, 124.6, 124.4, 123.5, 119.6, 111.5, 109.9, 109.5, 56.4, 56.0, 55.7, 51.8, 40.6, 33.0, 30.7.

(–)-Munitagine (6): white crystals; m.p. 168–169 °C; [α]D25 = −178° (c 0.26; CHCl₃); EI-MS (m/z) 327 (30), 326 (20), 190 (100); 1H-NMR (500 MHz, CDCl₃) δ 6.66 (1H, d, J = 8.2 Hz, H2), 6.66 (1H, s, H10), 6.64 (1H, s, H7), 5.72 (1H, s, OH), 4.38 (1H, d, J = 5.7 Hz, H5), 3.99 (1H, d, J = 5.7 Hz, H11), 3.83 (3H, s, OCH₃), 3.78 (3H, s, OCH₃), 3.43–3.31 (2H, m, H6, H12), 2.75 (1H, d, J = 16.1 Hz, H6), 2.62 (1H, d, J = 16.1 Hz, H12), 2.55 (3H, s, NCH₃); 13C-NMR (125 MHz, CDCl₃) δ 144.4, 144.1, 143.8, 141.8, 130.4, 125.5, 124.3, 124.3, 119.7, 112.7, 110.9, 109.2, 56.1, 56.0, 55.7, 51.8, 40.8, 32.9, 31.0.

(–)-Norargemonine (7): white crystals; m.p. 237–238 °C; [α]D25 = −152° (c 0.09; CHCl₃); EI-MS (m/z) 341 (60), 340 (35), 204 (95), 190 (100); 1H-NMR (500 MHz, CD₂OD) δ 6.76 (1H, s, H4), 6.73 (1H, s, H7), 6.56 (1H, s, H1), 6.41 (1H, s, H10), 4.04–4.00 (2H, m, H5, H11), 3.83 (3H, s, OCH₃), 3.81 (3H, s, OCH₃), 3.74 (3H, s, OCH₃), 3.42–3.35 (2H, m, H6, H12), 2.68–2.53 (2H, m, H6, H12), 2.49 (3H, s, NCH₃); 13C-NMR (125 MHz, CD₂OD) δ 149.5, 149.2, 147.9, 146.5, 131.1, 129.8, 125.3, 125.2, 116.0, 113.2, 111.9, 111.5, 57.6, 56.5, 56.4, 56.4, 40.7, 34.6, 34.3.

Purity of isolated compounds was ≥95% (by NMR and GC).

3.5. Biological Assays

3.5.1. Materials

Acetylthiocholine iodide (ATChI), butyrylthiocholine iodide (BTChI), berberine chloride (>95%), recombinant POP and its substrate, Z-Gly-Pro-p-nitroanilide (>99%) and eserine (>99%) were purchased from Sigma-Aldrich (Prague, Czech Republic); galanthamine hydrobromide (>98%) from Changsha Organic Herb Inc. (Changsha City, China), and huperzine A (98%) from Tai’an zhonghui Plant Biochemical Co., Ltd. (Xintai, China). Red blood cell lysate was used as a source of AChE, and human plasma as a source of BChE.

3.5.2. Preparation of Enzymes for AChE, BChE Assays

Enzymes were prepared from freshly drawn blood (taken from healthy volunteers), to which 2 mL 3.4% sodium citrate (v/v) per 18 mL blood was added, according to Steck and Kant [70], with slight modification. Briefly, plasma (BChE) was removed from the whole blood by centrifugation at 4000 rpm in a Boeco U-32R centrifuge fitted with a Hettich 1611 rotor. Red blood cells were transferred to 50 mL tubes and washed three times with 5 mM phosphate buffer (pH 7.4) containing 150 mM sodium chloride (centrifugation under same conditions). The washed erythrocytes were stirred with 5 mM phosphate buffer (pH 7.4) for 10 min to ensure lysis. The lysed cells were dispensed for subsequent measurement. Activity of each enzyme preparation was measured immediately after preparation and adjusted with 5 mM phosphate buffer (pH 7.4) to reach activity of blank sample A = 0.08–0.15 for AChE and A = 0.15–0.20 for BChE [71].
3.5.3. Cholinesterases Assays

AChE and BChE activities were determined using a modified Ellman’s method with ATChI and BTChI as substrates, respectively [36]. Briefly, 8.3 µL of either blood cell lysate or plasma dilutions (at least six different concentrations), 283 µL of 5 mM 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) and 8.3 µL of either the sample dilution in dimethyl sulfoxide (DMSO) (40 mM, 10 mM, 4 mM, 1 mM, 0.4 mM and 0 mM) or the blank sample (DMSO) were added into wells of a polystyrene 96-well microplate with a flat and clear bottom. The reaction was initiated by addition of 33.3 µL 10 mM substrate (ATChI or BTChI). The final proportion of DTNB and substrate was 1:1. The increase of absorbance (ΔA) at 436 nm for AChE and 412 nm for BChE was measured for 1 min at 37 °C using a spectrophotometer (SynergyTM HT Multi-Detection Microplate Reader). Each measurement was repeated six times for every concentration of enzyme preparation. The % inhibition was calculated according to the formula:

%I = 100 - \left(100 \times \frac{ΔA_{Bl}}{ΔA_{Sa}}\right)

where ΔA_{Bl} is the increase of absorbance of the blank sample and ΔA_{Sa} is the increase of absorbance of the measured sample. Inhibition potency of the tested compounds was expressed as an IC\(_{50}\) value (the concentration of an inhibitor, which causes 50% cholinesterase inhibition) [50].

3.5.4. Prolyl Oligopeptidase Assay

Prolyl oligopeptidase (POP; EC 3.4.21.26) was dissolved in phosphate buffered saline (PBS; 0.01 M Na/K phosphate buffer, pH 7.4, containing 137 mM NaCl and 2.7 mM KCl); the specific activity of the enzyme was 0.2 U/mL. The assay was performed in standard polystyrene 96-well microplates with a flat and clear bottom. Stock solutions of tested compounds were prepared in dimethyl sulfoxide (DMSO; 10 mM). Dilutions (10\(^{-3}\)–10\(^{-7}\) M) were prepared from the stock solution with deionized H\(_2\)O; the control was performed with the same DMSO concentration. POP substrate, (Z)-Gly-Pro-\(p\)-nitroanilide, was dissolved in 50% 1,4-dioxane (5 mM). For each reaction, PBS (170 µL), tested compound (5 µL), and POP (5 µL) were incubated for 5 min at 37 °C. Then, substrate (20 µL) was added and the microplate was incubated for 30 min at 37 °C. The formation of \(p\)-nitroanilide, directly proportional to the POP activity, was measured spectrophotometrically at 405 nm using a microplate ELISA reader (Multi-mode microplate reader Synergy 2, BioTek Instruments Inc., Winooski, VT, USA). Inhibition potency of tested compounds was expressed as an IC\(_{50}\) value [27].

3.5.5. Statistical Analysis

Calculations were performed using Microsoft Excel software (Redmont, WA, USA) and GraphPad Prism version 6.07 for Windows (GraphPad Software, San Diego, CA, USA).

4. Conclusions

This work focused on isolation of the tertiary alkaloids of *A. platyceras* and determination of their acetylcholinesterase, butyrylcholinesterase and prolyl oligopeptidase inhibitory activities. Seven alkaloids were isolated in sufficient amounts. (+)-Laudanosine, was isolated from *A. platyceras* for the first time. The alkaloids showed a dose-dependent inhibition in the enzyme assays. Some of them were tested for these biological effects for the first time. One of them, munitagine, is a pavine alkaloid, which was the most active compound. Moreover, considering the multifactorial pathological mechanisms of Alzheimer’s disease, an interesting finding is the dual activity of munitagine hitting two disorder targets— it inhibits acetylcholinesterase and prolyl oligopeptidase.

Acknowledgments: This project was supported by grants SVV 260401, SVV 260412 and Charles University grant Nr. 17/2012/UNCE.
Author Contributions: T.S., M.A., J.C., L.C. and J.K. contributed to the isolation of isoquinoline alkaloids and their unambiguous identification (MS, NMR, IR etc.). L.O., D.J. and M.H. contributed to the biological studies. J.C. designed the study, supervised the laboratory work and contributed to critical reading of the manuscript. All of the authors read the final manuscript and approved the submission.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Lleó, A. Current therapeutic options for Alzheimer’s disease. Curr. Genom. 2007, 8, 550–558. [CrossRef] [PubMed]
2. Park, S.Y. Potential therapeutic agents against Alzheimer’s disease from natural sources. Arch. Pharm. Res. 2010, 33, 1589–1609. [CrossRef] [PubMed]
3. Rasool, M.; Malik, A.; Qureshi, M.S.; Manan, A.; Pushparaj, P.N.; Asif, M.; Qazi, M.H.; Qazi, A.M.; Kamal, M.A.; Gan, S.H.; et al. Recent updates in the treatment of neurodegenerative disorders using natural compounds. Evid. Based Complement. Alternat. Med. 2014, 2014, 7. [CrossRef] [PubMed]
4. Nordberg, A.; Ballard, C.; Bullock, R.; Darreh-Shori, T.; Somogyi, M. A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer’s disease. Prim. Care Companion CNS Disord. 2013, 15. [CrossRef]
5. Standridge, J.B. Pharmacotherapeutic approaches to the treatment of Alzheimer’s disease. Clin. Ther. 2004, 26, 615–630. [CrossRef]
6. Greig, N.H.; Utsuki, T.; Yu, Q.; Zhu, X.; Holloway, H.W.; Perry, T.A.; Lee, B.; Ingram, D.K.; Lahiri, D.K. A New therapeutic target in Alzheimer’s disease treatment: Attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17, 159–165. [CrossRef] [PubMed]
7. Perry, E.K.; Atack, J.R.; Perry, R.H.; Hardy, J.A.; Dodd, P.R.; Edwardson, J.A.; Blessed, G.; Tomlinson, B.E.; Fairbairn, A.F. Intralaminar neurochemical distributions in human midtemporal cortex: Comparison between Alzheimer’s disease and the normal. J. Neurochem. 1984, 42, 1402–1410. [CrossRef] [PubMed]
8. Perry, E.K.; Tomlinson, B.E.; Blessed, G.; Bergmann, K.; Gibson, P.H.; Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978, 2, 1457–1459. [CrossRef] [PubMed]
9. Mukherjee, P.K.; Kumar, V.; Mal, M.; Houghton, P.J. Acetylcholinesterase inhibitors from plants. Phytomedicine 2007, 14, 289–300. [CrossRef] [PubMed]
10. Orhan, I.; Sener, B.; Choudhary, M.I.; Khalid, A. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J. Ethnopharmacol. 2004, 91, 57–60. [CrossRef] [PubMed]
11. Adsersen, A.; Gauguin, B.; Gudiksen, L.; Jäger, A.K. Screening of plants used in Danish folk medicine to treat memory dysfunction for acetylcholinesterase activity. J. Ethnopharmacol. 2006, 104, 418–422. [CrossRef] [PubMed]
12. Berkov, S.; Bastida, J.; Nikolova, M.; Viladomat, F.; Codina, C. Rapid TLC/GC-MS identification of acetylcholinesterase inhibitors in alkaloid extracts. Phytochem. Anal. 2008, 19, 411–419. [CrossRef] [PubMed]
13. Wilson, J.; Hayes, M.; Carney, B. Angiotensin-I-converting enzyme and prolyl endopeptidase inhibitory peptides from natural sources with a focus on marine processing by-products. Food Chem. 2011, 129, 235–244. [CrossRef]
14. López, A.; Tarragó, T.; Giralt, E. Low molecular weight inhibitors of prolyl oligopeptidase: A review of compounds patented from 2003 to 2010. Expert Opin. Ther. Pat. 2011, 21, 1023–1044.
15. Männistö, P.T.; García-Horsman, J.A. Mechanism of Action of prolyl oligopeptidase (PREP) in degenerative brain diseases: Has peptidase activity only a modulatory role on the interactions of PREP with proteins? Front. Aging Neurosci. 2017, 9. [CrossRef] [PubMed]
16. Brandt, I.; Scharpé, S.; Lambeir, A.M. Suggested functions for prolyl oligopeptidase: A puzzling paradox. Clin. Chim. Acta 2007, 377, 50–61. [CrossRef] [PubMed]
17. Morain, P.; Lestage, P.; de Nanteuil, G.; Jochemsen, R.; Robin, J.L.; Guez, D.; Boyer, P.A. S 17092: A prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev. 2002, 8, 31–52. [CrossRef] [PubMed]
18. Mellow, A.H.; Aronson, S.M.; Giordani, B.; Berent, S. A peptide enhancement strategy in Alzheimer’s disease; Pilot study with TRH-physostigmine infusions. Biol. Psychiatry 1993, 34, 271–273. [CrossRef]
19. Mellow, A.H.; Sunderland, T.S.; Cohen, R.M.; Lawlor, B.A.; Hill, J.L.; Newhouse, P.A.; Cohen, M.R.; Murphy, D.L. Acute effects of high-dose thyrotrophin-releasing hormone infusions in Alzheimer’s disease. *Psychopharmacol.* **1989**, *98*, 403–407. [CrossRef]

20. Tezuka, Y.; Fan, W.; Kasimu, R.; Kadota, S. Screening of crude drug extracts for prolyl endopeptidase inhibitory activity. *Phytomedicine* **1999**, *6*, 197–203. [CrossRef]

21. Ishiura, S.; Tsukahara, T.; Tabira, T.; Shimizu, T.; Arahata, K.; Sugita, H. Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase. *FEBS Lett.* **1990**, *260*, 131–134. [CrossRef]

22. Lawandi, J.; Gerber-Lemaire, S.; Juillerat-Jeanneret, L.; Moitessier, N. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: Defining diseases and inhibitors. *J. Med. Chem.* **2010**, *53*, 3423–3438. [PubMed]

23. Laitinen, K.S.M.; van Groen, T.; Tanila, H.; Venäläinen, J.; Männistö, P.T.; Alafuzoff, I. Brain prolyl oligopeptidase activity is associated with neuronal damage rather than β-amyloid accumulation. *Neuroreport* **2001**, *12*, 3309–3312. [CrossRef] [PubMed]

24. Morain, P.; Robin, J.L.; Nanteuil, G.D.; Jochemsen, R.; Heidet, V.; Guez, D. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study. *Br. J. Clin. Pharmacol.* **1998**, *45*, 580–585. [CrossRef]

25. Morain, P.; Boeijinga, P.H.; Demazière, A.; de Nanteuil, G.; Luthringer, R. Psychotropic Profile of S 17092, a prolyl endopeptidase inhibitor, Using quantitative EEG in young healthy volunteers. *Neuropsychobiology* **2007**, *55*, 176–183. [CrossRef] [PubMed]

26. Orhan, I.E. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer’s disease. *Curr. Med. Chem.* **2012**, *19*, 2252–2261. [CrossRef] [PubMed]

27. Cahliková, L.; Hulová, L.; Hrabinová, M.; Chlebek, J.; Hošt’álková, A.; Adamcová, M.; Šafratová, M.; Jun, D.; Opletal, L.; Ločárek, M.; et al. Isoquinoline alkaloids as prolyl oligopeptidase inhibitors. *Fitoterapia* **2015**, *103*, 192–196. [CrossRef] [PubMed]

28. Chlebek, J.; Novák, Z.; Kasemová, D.; Šafratová, M.; Kostelník, J.; Malý, L.; Ločárek, M.; Opletal, L.; Hošt’álková, A.; Hrabinová, M.; et al. Isoquinoline alkaloids from *Fumaria officinalis* L. and their biological activities related to Alzheimer’s disease. *Chem. Biodivers.* **2016**, *13*, 91–99. [CrossRef] [PubMed]

29. Cahliková, L.; Hrabinová, M.; Kulhánková, A.; Benešová, N.; Chlebek, J.; Jun, D.; Novák, Z.; Macáková, K.; Kuneš, J.; Kuča, K.; et al. Alkaloids from *Chlidanthus fragrans* and their acetylcholinesterase, butyrylcholinesterase and prolyl oligopeptidase *Nat. Prod. Commun.* **2013**, *8*, 1541–1544. [PubMed]

30. Schwarzbach, A.E.; Kaderiet, J.W. Phylogeny of prickly poppies, *Argemone* (Papaveraceae), and the evolution of morphological and alkaloid characters based on ITS nrDNA sequence variation. *Plant Syst. Evol.* **1999**, *218*, 257–279. [CrossRef]

31. Fernandez, J.; Reyes, R.; Ponce, H.; Orupeza, M.; Vancelsteren, M.R.; Jankowski, C.; Campos, M.G. Isoquercitrin from *Argemone platyceras* inhibits carbachol and leukotriene D4-induced contraction in guinea-pig airways. *Eur. J. Pharmocol.* **2005**, *522*, 108–115. [CrossRef] [PubMed]

32. Boit, H.G.; Flenjté, H. Alkaloiode aus *Argemone platyceras*. Naturwissenschaften **1960**, *47*, 323.

33. Slavík, J.; Slavíková, L. Alkaloiode der Mohngewächse (Papaveraceae) XII. Über die Alkaloiode aus *Argemone platyceras* Link et Otto. *Coll. Czech. Chem. Commun.* **1963**, *28*, 1728–1737. [CrossRef]

34. Slavík, J.; Slavíková, L.; Haisová, K. Alkaloids of the Papaveraceae. L. On the quaternary alkaloids from *Argemone platyceras* Link et Otto. *Coll. Czech. Chem. Commun.* **1973**, *38*, 2513–2517. [CrossRef]

35. Israilov, I.A.; Yunusov, M.S. Alkaloids of four species of *Argemone*. *Chem. Nat. Comp.* **1986**, **22**, 189–192. [CrossRef]

36. Chelombitko, V.A.; Nazarova, L.E. Alkaloids from several *Argemone* species. *Pharm. Chem. J.* **1988**, *22*, 580–585.

37. Slavík, J.; Slavíková, L. Quaternary alkaloids from the roots of *Argemone platyceras* Link et Otto. *Coll. Czech. Chem. Commun.* **1976**, *41*, 285–289. [CrossRef]

38. Cahliková, L.; Kučera, R.; Hošt’álková, A.; Klímeš, J.; Opletal, L. Identification of pavinane alkaloids in the genera *Argemone* and *Eschscholzia* by GC-MS. *Nat. Prod. Commun.* **2012**, *7*, 1279–1281. [PubMed]

39. Khorana, N.; Markmee, S.; Ingkaninan, K.; Ruchirawat, S.; Kitbunndaj, R.; Pullagurla, M.R. Evaluation of new lead for acetylcholinesterase inhibition. *Med. Chem. Res.* **2009**, *18*, 231–241. [CrossRef]

40. Castaing, N.; Benali, L.; Ducint, D.; Molimard, M.; Gromb, S.; Titier, K. Suicide with cisatracurium and thiopental: Forensic and analytical aspects. *J. Anal. Toxicol.* **2011**, *35*, 375–380. [CrossRef] [PubMed]
41. Janssen, R.H.A.M.; Wijiksens, P.; Kruk, C.; Biessels, H.W.A.; Menichini, F.; Theuns, H.G. Assignments of $^1$H and $^{13}$C-NMR resonances of some isoquinoline alkaloids. *Phytochemistry* 1990, 29, 3331–3339. [CrossRef]
42. Takahashi, H.; Iguchi, M.; Onda, M. Utilization of protopine and related alkaloids. XVII. Spectroscopic studies on the ten-membered ring conformations of protopine and $\alpha$-allocryptopine. *Chem. Pharm. Bull.* 1985, 33, 4775–4782. [CrossRef]
43. Leyva-Peralta, M.A.; Robles-Zepeda, R.E.; Garibay-Escobar, A.; Ruiz-Bustos, E.; Alvarez-Berber, L.P.; Gálvez-Ruiz, J.C. In vitro anti-proliferative activity of *Argemone gracilenta* and identification of some active components. *BMC Complement. Alternat. Med.* 2015, 15, 13. [CrossRef] [PubMed]
44. Shamma, M.; Moniot, J.L. A novel isoquinoline alkaloid group. The aporphine-pavine dimers. *J. Am. Chem. Soc.* 1974, 96, 3338–3340. [CrossRef]
45. Lee, S.S.; Doskotch, R.W. Four dimeric aporphine-containing alkaloids from *Thalictrum fauriei*. *J. Nat. Prod.* 1999, 62, 803–810. [CrossRef] [PubMed]
46. Stermitz, F.R.; Seiber, J.N. Alkaloids of the Papaveraceae. IV. *Argemone hispida* and *A. munita* subspecies rountadata. *J. Org. Chem.* 1966, 31, 2925–2933.
47. Stermitz, F.R.; Seiber, J.N. Alkaloids of Papaveraceae. III. Synthesis and structure of norargemonine. *Tetrahedron Lett.* 1966, 11, 1177–1183. [CrossRef]
48. Benn, M.H.; Mitchell, R.E. Alkaloids of *Argemone grandiflora*. *Phytochemistry* 1972, 11, 461–464. [CrossRef]
49. Dang, T.T.T.; Facchini, P.J. Characterization of three O-methyltransferases involved in noscapine biosynthesis in opium poppy. *Plant Physiol.* 2012, 159, 618–631. [CrossRef] [PubMed]
50. Vacek, J.; Walterová, D.; Vrublová, E.; Šimánek, V. The chemical and biological properties of protopine and allocryptopine. *Heterocycles* 2010, 81, 1773–1789. [CrossRef]
51. Gözler, B.; Lantz, M.S.; Shamma, M. The paveine and isopaveine alkaloids. *J. Nat. Prod.* 1983, 46, 293–309. [CrossRef]
52. Ehret, M.J.; Chamberlin, K.W. Current practices in the treatment of Alzheimer disease: Where is the evidence after the phase III Trials? *Clin. Ther.* 2015, 37, 1604–1616. [CrossRef] [PubMed]
53. Anand, R.; Gill, K.D.; Mahdi, A.A. Therapeutics of Alzheimer’s disease: Past, present and future. *Neuropharmacology* 2014, 76, 27–50. [CrossRef] [PubMed]
54. Schneider, L.S.; Mangialasche, F.; Andresen, N.; Feldman, H.; Giacobini, E.; Jones, R.; Mantua, V.; Mecocci, P.; Pani, L.; Winblad, B.; et al. Clinical trials and late-stage drug development for Alzheimer’s disease: An appraisal from 1984 to 2014. *J. Intern. Med.* 2014, 275, 251–283. [CrossRef] [PubMed]
55. Giacobini, E. Cholinesterase inhibitors: New roles and therapeutic alternatives. *Pharmacol. Res.* 2004, 50, 433–440. [CrossRef] [PubMed]
56. Kandiah, N.; Pai, M.; Senanarong, V.; Looi, I.; Ampil, E.; Park, K.W.; Karanam, A.K.; Christopher, S. Rivastigmine: The advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. *Clin. Interv. Aging* 2017, 12, 697–707. [CrossRef] [PubMed]
57. Ellman, G.L.; Courtney, K.D.; Andres, V.; Featherstone, R.M. A new rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* 1961, 7, 88–95. [CrossRef]
58. Cahlíková, L.; Macáková, K.; Kuneš, J.; Kurfürst, M.; Opletal, L.; Cvačka, J.; Chlebek, J.; Blunden, G. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from *Eschscholzia californica* (Papaveraceae). *Nat. Prod. Commun.* 2010, 5, 1035–1038. [PubMed]
59. Sener, B.; Orhan, I. Discovery of drug candidates from some Turkish plants and conservation of biodiversity. *Pure Appl. Chem.* 2005, 77, 53–64. [CrossRef]
60. Hošt’áliková, A.; Opletal, L.; Kuneš, J.; Novák, Z.; Hrabinová, M.; Chlebek, J.; Čegan, L.; Cahlíková, L. Alkaloids from *Pauwuus boldus* and their acetylcholinesterase, butyrylcholinesterase and propyl oligopeptidase inhibition activity. *Nat. Prod. Commun.* 2015, 10, 577–580. [PubMed]
61. Chlebek, J.; Macáková, K.; Cahlíková, L.; Kurfürst, M.; Kuneš, J.; Opletal, L. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from *Corydalis cava* (Fumariaceae). *Nat. Prod. Commun.* 2011, 6, 607–610. [PubMed]
62. Markmee, S.; Ruchirawat, S.; Prachyawararakorn, V.; Ingkaninan, K.; Khorana, N. Isoquinoline derivatives as potential acetyl-cholinesterase inhibitors. *Bioorg. Med. Chem. Lett.* 2006, 16, 2170–2172. [CrossRef] [PubMed]
63. Sener, B.; Orhan, I. Molecular diversity in the bioactive compounds from Turkish plants—evaluation of acetylcholinesterase inhibitory activity of *Fumaria* species. *J. Chem. Soc. Pak.* 2004, 26, 313–315.
64. Brunhofer, G.; Karlsson, D.; Batista-Gonzalez, A.; Shinde, P.C.; Mohan, C.G.; Vuorela, P. Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: The case of chelerythrine. *Bioorg. Med. Chem.* 2012, 20, 6669–6679. [CrossRef] [PubMed]

65. Ji, H.F.J.; Shen, L. Berberine: A potential multipotent natural product to combat Alzheimer’s disease. *Molecules* 2011, 9, 6732–6740. [CrossRef] [PubMed]

66. Jung, H.A.; Min, B.S.; Yokozawa, T.; Lee, J.H.; Kim, Y.S.; Choi, J.S. Anti-Alzheimer and antioxidant activities of *Coptidis rhizoma* alkaloids. *Biol. Pharm. Bull.* 2009, 32, 1433–1438. [CrossRef] [PubMed]

67. Kukula-Koch, W.; Mroczek, T. Application of hydrostatic CCC-TLC-HPLC-ESI-TOF-MS for the bioguided fractionation of anticholinesterase alkaloids from *Argemone mexicana* L. roots. *Anal. Bioanal. Chem.* 2015, 407, 2581–2589. [CrossRef] [PubMed]

68. Lu, Y.C.; Lin, Q.; Luo, G.S.; Dai, Y.Y. Solubility of berberine chloride in various solvents. *J. Chem. Eng. Data* 2006, 51, 642–644. [CrossRef]

69. NCBI. PubChem. Pubchem Compound. Available online: https://www.ncbi.nlm.nih.gov/pccompound (accessed on 15 May 2017).

70. Steck, T.L.; Kant, J.A. Preparation of impermeable ghosts and inside-out vesicles from human erythrocyte membranes. *Methods Enzymol.* 1974, 31, 172–180. [PubMed]

71. Vaněčková, N.; Hošťálková, A.; Šafratová, M.; Kuneš, J.; Hulcová, D.; Hrabinová, M.; Doskočil, I.; Štěpánková, Š.; Opletal, L.; Nováková, L.; et al. Isolation of Amaryllidaceae alkaloids from *Nerine bowdenii* W. Watson and their biological activities. *RSC Adv.* 2016, 6, 80114. [CrossRef]

**Sample Availability:** Samples of the compounds, except 2 and 4, are not available from the authors.